Summit Therapeutics Reports Ivonescimab Plus Chemotherapy Improves Survival in EGFR-Mutated NSCLC Phase III Trial

Reuters11-07
<a href="https://laohu8.com/S/SMMT">Summit</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Ivonescimab Plus Chemotherapy Improves Survival in EGFR-Mutated NSCLC Phase III Trial

Summit Therapeutics Inc. announced that results from the Phase III HARMONi-A clinical trial, conducted by its partner Akeso, Inc. in China, have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025). The trial evaluated the investigational bispecific antibody ivonescimab in combination with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who had previously received a third-generation EGFR TKI. The study demonstrated a statistically significant benefit in overall survival, with a reported hazard ratio of 0.74. The safety profile of ivonescimab in combination with chemotherapy was described as manageable. In May 2024, Akeso announced the approval of ivonescimab plus chemotherapy in this treatment setting in China, following the HARMONi-A trial results. An administrative review of overall survival at 52% data maturity reported a hazard ratio of 0.80 (95% CI: 0.59, 1.08) with a data cutoff in December 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107747347) on November 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment